Additionally, western blotting validates the expression of FTH1, GPX4, SLC7A11, FSP1 and DHODH in fresh surgical tumour tissues from three imatinib‐resistant patients compared with three imatinib‐sensitive patients receiving neoadjuvant imatinib therapy (Figure 1I). Here, GPX4 is linked to neoplasm.